摘要
目的探讨巴曲酶联合银杏达莫治疗脑梗死的疗效和安全性。方法将我院收治的88例脑梗死患者随机分为两组各44例。对照组采用银杏达莫治疗，治疗组采用巴曲酶联合银杏达莫治疗，观察治疗前和治疗后第7d、第14d、第21d的美国国立卫生院神经功能缺损评分(NIHSS)和日常生活能力评分(Barthel index，BI)以及其安全性情况。结果治疗前两组NIHSS评分、BI评分均无统计学差异(P >0.05)，治疗后第7d、第14d、第21d时两组比较有统计学差异(P <0.05)；均无明显出血发生。结论巴曲酶联合银杏达莫治疗急性脑梗死疗效优于单药治疗，安全性好。
Abstract
Objective To study the Batroxobin and Ginkgo leaf Extract and Dipyridamole in the treatment of cerebral infarction efficacy and safety. Methods 88 cases were our of cerebral infarction were randomly divided into control group and treatment group 44 cases each. The comparison group use the Ginkgo leaf Extract and Dipyridamole treatment, the treatment group use the Batroxobin and Ginkgo leaf Extract and Dipyridamole treatment, observation before treatment and after treatment 7, 14, 21 days of the U.S. national institutes of nerve function defect score(NIHSS) scores and daily life ability score(Barthel index, BI) as well as the security situation. Results The two groups before treatment NIHSS score, BI scores are no statistical difference(P >0.05), the seventh day after treatment, day 14, 21 days between the two groups have statistical difference(P <0.05); Two groups were not significantly bleeding occurred. Conclusion The Batroxobin and Ginkgo leaf Extract and Dipyridamole treatment of patients with acute cerebral infarction curative effect is better than the single drug treatment, and good safety.
NETL
NSTL
维普
万方数据